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Abstract
Harmine, a b-carboline alkaloid, is a high affinity inhibitor of the dual specificity tyrosine phosphorylation regulated kinase
1A (DYRK1A) protein. The DYRK1A gene is located within the Down Syndrome Critical Region (DSCR) on chromosome 21.
We and others have implicated DYRK1A in the phosphorylation of tau protein on multiple sites associated with tau
pathology in Down Syndrome and in Alzheimer’s disease (AD). Pharmacological inhibition of this kinase may provide an
opportunity to intervene therapeutically to alter the onset or progression of tau pathology in AD. Here we test the ability of
harmine, and numerous additional b-carboline compounds, to inhibit the DYRK1A dependent phosphorylation of tau
protein on serine 396, serine 262/serine 356 (12E8 epitope), and threonine 231 in cell culture assays and in vitro
phosphorylation assays. Results demonstrate that the b-carboline compounds (1) potently reduce the expression of all three
phosphorylated forms of tau protein, and (2) inhibit the DYRK1A catalyzed direct phosphorylation of tau protein on serine
396. By assaying several b-carboline compounds, we define certain chemical groups that modulate the affinity of this class
of compounds for inhibition of tau phosphorylation.
Citation: Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, et al. (2011) b-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau
Phosphorylation at Multiple Alzheimer’s Disease-Related Sites. PLoS ONE 6(5): e19264. doi:10.1371/journal.pone.0019264
Editor: Efthimios M. C. Skoulakis, Alexander Flemming Biomedical Sciences Research Center, Greece
Received January 4, 2011; Accepted March 24, 2011; Published May 6, 2011
Copyright:  2011 Frost et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by R21AG029576, K01AG024079, P30AG19610 to TD, the Arizona Alzheimer’s Research Consortium, and a charitable
contribution to TGen from the Louis Charitable Trust. Studies of MPP-021 and MPP-313 were supported by MediProPharma, Inc. MediProPharma provided
information about compound solubility and IC50 data to assist in compound dosing. Aside from this, the funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Studies involving the compounds MPP-021 and MPP-313 were funded by MediProPharma, Inc. For these studies, MediProPharma
provided TGen with adequate amounts of each compound, their data determining the IC50’s for these compounds against DYRK1A, and paid TGen’s reagent
costs to analyze these compounds. The specific experiments performed were conceived, carried out, and analyzed by TGen with no subsequent input from
MediProPharma. Proprietary MPP compounds are available from MediProPharma through completion of a material transfer agreement. MediProPharma’s role in
this study does not alter our adherence to PLoS One’s policy for sharing data and materials.
* E-mail: tdunckley@tgen.org
Introduction
The dual-specificity tyrosine phosphorylation regulated kinase
1A (DYRK1A) gene is located within the Down syndrome critical
region on chromosome 21. Overexpression of DYRK1A has been
proposed to be a significant contributor to the underlying
neurodevelopmental abnormalities associated with Down syn-
drome. Transgenic animals overexpressing DYRK1A show
marked cognitive deficits and impairment in hippocampal
dependent memory tasks [1,2]. Studies in cell culture models
and transgenic models of Down syndrome that overexpress
DYRK1A implicate the DYRK1A kinase in the generation of
both amyloid and tau pathologies associated with the early onset
Alzheimer’s disease (AD) that is uniformly observed in Down
Syndrome [3,4,5,6]. We and others have shown that DYRK1A is
important for phosphorylation of tau protein on multiple sites in
several cellular models [3,4,6,7]. Interestingly, DYRK1A protein
has been found to be associated with neurofibrillary tangles (NFTs)
in sporadic Alzheimer’s disease [8] and some studies have found a
genetic association between SNPs within the DYRK1A locus and
Alzheimer’s disease in some populations [3] but not others [9].
These combined observations raise the possibility that DYRK1A
may be a critical contributor to tau dysfunction and tau pathology
of Alzheimer’s disease and, moreover, that this kinase may be an
important therapeutic target for pharmacological interventions
seeking to modify the course of tau pathology in AD.
The family of b-carboline alkaloids, characterized by a core
indole structure and a pyridine ring, are naturally occurring
compounds in some plant species that affect multiple central
nervous system targets. These include the 5-hydroxytryptamine
receptor substypes 5-HT2 and 5-HT1A [10], the NMDA receptor
[11], monoamine oxidase (MAO-A) [12], and dopaminergic
signaling pathways [13,14,15]. In addition to these targets, the
b-carboline alkaloid, harmine, has recently been reported to be a
high affinity inhibitor of DYRK1A kinase activity [16,17],
suggesting that harmine, and possibly other b-carboline deriva-
tives, could alter tau phosphorylation.
In this study, we extend previous published findings from our
lab and others that show DYRK1A is involved in phosphorylation
of tau protein on sites that are hyperphosphorylated during the
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alkaloids can significantly reduce the levels of phosphorylated tau
protein. Specifically, we identify DYRK1A dependent tau
phosphorylation on threonine 231 and serine 396. We further
show that harmine and other b-carboline compounds inhibit
DYRK1A dependent tau phosphorylation with varying affinities
that are dependent upon several structural features of the
molecules. These results suggest that this class of compounds
warrant further investigation as candidate tau-based therapeutics
to alter the onset or progression of tau dysfunction and pathology
in Alzheimer’s disease and other tauopathies.
Methods
siRNA transfection
4R0N tau overexpressing H4 neuroglioma cells [7] were
maintained in Dulbecco’s Modified Eagle Medium (Invitrogen)
supplemented with 10% fetal bovine serum (Invitrogen), 1%
penicillin-streptomycin, geneticin (0.25 mg/ml), and 2 mM L-
Glutamine (Invitrogen). Cells were maintained by splitting 1:10 at
90% confluency. Prior to any experimentation, cells were 70–75%
confluent to ensure cells were in their active growth phase. To test
effects of DYRK1A knockdown on tau phosphorylation, cells were
transfected with DYRK1A siRNA. Prior to treating cells with
DYRK1A siRNA, siRNA was first complexed with siLentfect lipid
transfection reagent (Bio-Rad) and reduced serum medium
(Invitrogen) using a 6 well plate format. The final effective siRNA
molarity used was 22.85 nM per well. Cells were grown for
96 hours at 37uC, 5% CO2. Cell lysates were prepared using the
Complete Lysis-M, EDTA-free kit (Roche Applied Science) and
total protein concentration was quantified using the BCA protein
assay (Pierce). Westerns for the multiple forms of tau were
performed as described below.
Western Blotting
For all cell-based experiments, including siRNA treatments
and compound treatments, cells were treated for 96 hours at
37uC, with 5% CO2. Cell lysates were then prepared using the
Complete Lysis-M, EDTA-free kit (Roche Applied Science)
supplemented with phosphatase inhibitor cocktails 1 and 2
(Sigma). Lysates were quantified using the BCA protein assay
(Pierce). Protein from lysates (30 mg total protein per lane) was
separated on SDS-PAGE gels and transferred to nitrocellulose
membrane. Membranes were blocked in 5% blocking solution for
one hour at room temperature (RT). Blocking buffer solution
used for detection of non phosphorylated protein contained 5%
Non-fat dry milk in 16-TBS-T (50 mM Tris-HCl pH 7.4,
137 mM NaCl2, 2.7 mM KCl, 0.1% Tween). For detection of
phosphorylated protein, blocking buffer solution contained 5%
Bovine Serum Albumin in 16TBS-T. Membranes were probed
with primary antibody (various dilutions depending on the
epitope – see below) in blocking buffer overnight at 4uCo na
rocker. Membranes were subsequently washed with 16 TBS-T
and probed with secondary antibody in blocking buffer for forty-
five minutes using a 1:25,000 dilution of HRP-GAM or HRP-
GAR (Jackson Immunoresearch), depending on the species
(mouse or rabbit) in which the primary antibodies were raised.
Following incubation with secondary antibody, membranes were
washed in 16 TBS-T and developed with Super Signal West
Femto Maximum Sensitivity Substrate Kit (Promega) and
digitally imaged. Protein band signal saturation was assessed
before any further analysis of multiple forms of tau. Alpha
Innotech Fluoro Chem SF imaging software verifies degrees of
saturation when signal intensity is beyond the dynamic range
(which is from 0–65,535). Protein band signal intensities used for
quantification were within the instrument’s dynamic range.
To test multiple primary antibodies, membranes were stripped
for 15 minutes at RT using ReBlot Plus Mild Antibody Stripping
Solution (Millipore). Membranes were then washed for 5 minutes
in 16TBS-T and blocked for one hour in 5% blocking solution at
RT. For verification of protein loading, membranes were reprobed
overnight at 4uC with an anti-Tubulin primary antibody (1:1000
dilution; Cell Signaling). Primary antibodies used for detection
included anti-tau (1:2000 dilution; Dako), 12E8 tau (1:7500
dilution; Peter Seubert, Elan Pharmaceuticals), pT231 tau
(1:1000 dilution; Abcam), pS396 tau (1:5000 dilution; Abcam),
and anti-DYRK1A (1:500 dilution; Santa Cruz).
Compound treatments
Cells undergoing any treatment, including b-carboline deriva-
tive dosing and siRNA treatment, were maintained in Dulbecco’s
Modified Eagle Medium (Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen) and 2 mM L-Glutamine (Invitrogen).
Viability assays were performed using a 96-well pate format.
Metabolic activity was measured 12 hours after the addition of
10% alamar Blue (Invitrogen) directly to attached cells in full
medium. This assay was based on the ability of metabolically
active cells to convert alamar Blue reagent into a fluorescent signal
proportional to innate metabolic activity. Once the ideal IC50
value for viability was identified, effects on multiple forms of tau
were investigated after treating with the b-carbolines indicated in
Table S1 using the larger 6 well plate format. For both the viability
assay and cell culture tau assays, cell culture media was removed
and cells were treated with freshly made drug in new media every
24 hours for four days. For cell culture tau assays, protein lysates
were prepared after 96 hours of treatment. All compounds were
solubilized in dimethylsulfoxide (DMSO), diluted in growth
medium to their respective 0.01 mM, 0.1 mM, 1 mM and 10 mM
final working dilutions and added directly to cultured cells. The
final DMSO percentage in culture for all compounds and
concentrations tested was 0.1%. All treatments conditions were
compared to their respective controls which contained DMSO at
0.1% in growth medium.
In Vitro Kinase Assay
Evaluation of DYRK1A kinase activity was determine by
incubating 0.08 ug of recombinant human DYRK1A protein
(Invitrogen) with 0.15 ug of 4R2N recombinant human Tau
(SignalChem) in 16 kinase buffer (25 mM Tris-HCl (pH 7.5),
5 mM beta-glycerophosphate, 2 mM dithiothreitol (DTT),
0.1 mM Na3VO4, 10 mM MgCl2 - Cell Signal) and 1 mM
ATP in a final volume of 20 ul for 30 minutes @ 30C. For testing
the effects of the b-carboline derivatives, recombinant human
DYRK1A was pretreated with compounds for 10 minutes prior to
the addition of kinase buffer, ATP, and recombinant human tau.
The reaction was inactivated upon addition of 16 Novex LDS
sample buffer and Novex sample reducing reagent, 50 mM DTT,
(Invitrogen) followed immediately by heating for 10 minutes @
95C. Phosphorylated Tau was resolved using 7% Tris Acetate gels
and detected by western analysis. Westerns were probed for
Phospho-Tau S396 (abcam) @ 1:5,000 dilution and a secondary of
Goat anti – Rabbit HRP (Jackson Immuno Labs) @ 1:50,000 in
5% BSA. Membranes were stripped as above and reprobed with
rabbit anti Human Total Tau (Dako) @ 1:15,000 dilution and a
secondary of Goat anti – Rabbit HRP (Jackson Immuno labs) @
1:100,000 dilution in 5% milk. For quantitation purposes, both
bands of pS396 phosphorylated tau were used in the in vitro
phosphorylation assays.
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Reduced DYRK1A expression affects tau phosphorylation
at multiple sites
We previously reported that silencing of DYRK1A expression
causes reduced tau phosphorylation at the 12E8 epitope (phosphor-
ylated serines 262 and 356) [7]. Here we show that RNAi-mediated
silencing of DYRK1A expression simultaneously affects multiple
additional AD-relevant tau phosphorylation sites, including threonine
231 and serine 396 (Figure 1). We transfected H4 neuroglioma cells
that overexpress 4R0N tau with siRNA specific for DYRK1A.
Results showed that reduction of DYRK1A expression to 38% of
control leads to pT231 and pS396 tau expression that is 48% and
35% of control nonsilencing siRNA, respectively. These results are
consistent with the hypothesis that DYRK1A may be a promiscuous
tau kinase and are also consistent with prior studies that have shown
DYRK1A phosphorylation of tau on several other sites, including
threonine 212 [3,4], serine202, and serine 404 [6]. The finding that
DYRK1A is involved in the phosphorylation of sites that control key
microtubule binding functions of tau (S262, T231), as wellas sites that
are phosphorylated relatively late during the formation of neurofi-
brillary tangles (S396, S404), raises the interesting possibility that
DYRK1A could be an important site of regulatory control for tau
function and for the formation of tau pathology during the
progression of tauopathies.
The high affinity DYRK1A inhibitor, harmine, affects tau
phosphorylation on multiple sites
Harmine, a naturally occurring b-carboline alkaloid, is a potent
inhibitor of DYRK1A with a reported IC50 of ,80 nM in an in vitro
kinase assay using synthetic peptide substrate [17]. Based on our
findings that DYRK1A silencing reduces multiple phosphorylated
tau species, we tested harmine for effects on tau phosphorylation in
the H4neuroglioma cellline. We first determined the toxicity profile
for harmine (Figure 2A). Results of increasing concentrations of
harmine showed that 12 mM resulted in 50% cell viability. Based on
this toxicity profile and the reported in vitro IC50 value for harmine
against DYRK1A, we selected doses of 80 nM, 800 nM and 8 mM
for the tau phosphorylation assays. Harmine reduced the expression
of each phospho-tau species tested, including 12E8 (pS262/pS356),
pT231, and pS396 (Figure 2B). Significant (P,0.05) reductions to
12E8 and pT231 tau were noted at 0.8 mMa n d8mMc o n c e n t r a -
tions. However, it is important to note that harmine at 0.8 mMa n d
8 mM also reduced the levels of total tau protein consistent with the
reductions detected with the various phospho-tau antibodies. Even
accounting for reductions to total tau levels, significant reductions to
12E8 (58% of control) and pT231 (44% of control) levels remained
(Figure 2B). pS396 effects are largely accounted for by overall
reductions to total tau levels.
In addition to DYRK1A inhibition, harmine has been reported to
be a selective inhibitor of monoamine oxidase (MAO-A) [12]. To test
if effects on tau could result from MAO-A inhibition, we tested
another MAO-A selective antagonist, moclobemide, for effects on
tau. Moclobemide has a reported IC50 against MAO-A of 3.9 mM
[18]. Results showed that this MAO-A antagonist did not reduce
levels of either total tau or of specific phosphorylated forms of tau
protein at doses up to 500 mM (Figure 2C). These results suggest that
the effects of harmine on tau do not result from MAO-A inhibition.
Additional b-carboline alkaloid derivatives alter the
expression of multiple tau species
Based on results for harmine, we tested additional b-carboline
derivatives, includingharmol,harmane, harmaline, norharmane, 9-
ethylharmine, and two novel proprietary compounds MPP-021 and
MPP-313 (MediProPharma, Inc.: patents pending). We first
performed toxicity assays for each compound in our H4 cell line
(Table S1). We then tested each compound for effects on phospho-
tau and total tau expression (Figure 3). Quantification of
phosphorylated tau levels is shown in Figure 4. Data for
phosphorylated tau levels have been corrected for effects of the
compounds on total tau levels. Quantification of absolute phospho-
tau levels is included as supplementary material (Figure S1). There
was a positive correlation between the toxicity of each compound
and the sensitivity with which each compound reduced total
tau levels and the levels of phosphorylated forms of tau. For toxicity,
the rank order of the compounds was 9-ethylharmine.harmine.
harmol.harmane.harmaline.MPP-021.norharmane.MPP-313.
In terms of the sensitivity with which each compound reduced tau
levels, only 9-ethylharmine, harmine, and harmol showed significant
effects (p,0.05) in reducing total tau and phosphorylated tau levels at
doses $1 mM. As with harmine results in Figure 2, reductions to 12E8
tau and pT231 tau remained significant after accounting for total tau
reductions (Figure 4). MPP-021 and MPP-313 significantly reduced
(p,0.05) tau levels at 50 mM. The 9-ethylharmine and harmine
compound treatments showed significant reductions at 1 mMa n d
0.8 mM, respectively. These lower doses have no detectable effect on
the viability of the cells. We therefore conclude that reducing tau levels
beyond ,50% of the control levels, as occurs at higher concentrations,
leads to significant cellular toxicity rather than the alternative of the
observed reductions in tau resulting from general drug-induced
toxicity.
Harmine and other b-carboline compounds inhibit the
direct phosphorylation of tau by DYRK1A
DYRK1A has been reported to directly phosphorylate tau
protein onT212,S202,and S404[3,4,6].To determineif the effects
Figure 1. DYRK1A is required for efficient phosphorylation of
pT231, pS396 and 12E8 tau. H4 neuroglioma cells overexpressing
four repeat tau (4R0N) were transfected with siRNA targeting the
DYRK1A transcript. Silencing of DYRK1A was confirmed with anti-
DYRK1A antibody (top panel). Percent control values represent the
average of three independent siRNA transfections and westerns. NS
refers to the non-silencing control. 12E8 refers to the dual phosphor-
ylation epitope pS262/pS356.
doi:10.1371/journal.pone.0019264.g001
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from the inhibition of direct phosphorylation of tau protein by
DYRK1A, we first tested if DYRK1A could directly phosphorylate
serine396. Usinganin vitrophosphorylationassaywith recombinant
DYRK1A and tau proteins, we confirmed that DYRK1A could
directly phosphorylate tau protein (Figure 5A). Phosphorylation
occurred only inthe presenceof tau protein, DYRK1Aprotein, and
ATP. We observed a doublet of pS396 phosphorylated tau. Because
the primary protein band recognized by the total tau antibody is the
molecular weight of the lower band of this pS396 doublet, the
doublet is unlikely to result from any protein degradation. Rather, it
may be that the higher molecular weight band contains phosphor-
ylations inaddition to serine396. Thisexplanationis consistentwith
reported literature indicating a role for DYRK1A in the
phosphorylation of tau protein on S202, S404, and T212 [3,4,6].
The observed pS396 tau phosphorylation was potently inhibited by
harmine with an IC50 of 0.7 mM (Figure 5B).
We next tested each b-carboline derivative compound in this in
vitro assay (Figure 6 and Figure 7). Several interesting observations
emerged from this series of studies. We first determined the IC50
values for each compound for the inhibition of DYRK1A
dependent tau phosphorylation at serine 396. These results reflect
the rank ordered affinities for each compound that were obtained in
the cell based tau phosphorylation assays and the toxicity assays
(Table S1 and Figures 2B and Figure 3), with one exception.
Harmol was the most potent inhibitor in this in vitro phosphorylation
assay with an IC50 of 90 nM, followed by 9-ethylharmine (400 nM)
and harmine (700 nM). Harmol was the third ranked compound in
both the toxicity and cell-based tau assay. Reasons for this slight
disconnect are unclear, but could be related to differential cellular
metabolism of the free hydroxyl group on carbon 7 of harmol.
The addition of an ethyl group to N-9 of harmine reduced the
IC50 nearly 2-fold, suggesting that additional modifications on this
nitrogen might increase the affinity of harmine for DYRK1A more
substantially. Harmane, norharmane, and harmaline were more
than an order of magnitude lower affinity than harmine, consistent
with the relatively muted effects of these compounds in our cell-
based tau assay (Figure 3).
The MPP-313 compound reduced phosphorylation of the lower
molecular weight form of phosphorylated tau protein with an IC50 of
5 mM. However, effects on the larger molecular weight band were
striking. Levels of this larger phosphorylated tau protein decline to
near 50% of the no drug treated sample at a concentration of 5 mM,
but thensharplyreverse and increasesignificantlybeyondthenodrug
treated control at doses of 50 mM (255% control) and 100 mM (640%
control) (Figure 6). This was the only b-carboline derivative tested
that displayed this pattern. All other compounds showed consistent
effects on both molecular weight forms of pS396 tau. While we
cannot yet explain this observation, it does suggest that at higher
concentrations MPP-313 induces DYRK1A activity through a yet-to-
be determined mechanism.
Discussion
DYRK1A is involved in phosphorylation of multiple sites
on tau
Previous literature indicates that DYRK1A can phosphorylate
tau protein on T212, S202, S404, and the 12E8 epitope (S262/
S356) [3,4,6,7]. Here we provide evidence that DYRK1A is also
involved in tau phosphorylation at threonine 231 and serine 396
(Figure 1). This growing list of phosphorylation sites affected by
DYRK1A, which now includes key sites regulating microtubule
affinity (T231, S262) [19,20] and references therein], tau toxicity
(T231, S262, T212) [21], and sites hyperphosphorylated coinci-
Figure 2. Harmine, a DYRK1A antagonist, inhibits tau phos-
phorylation. Shown in (A) is the toxicity profile of harmine against the
H4 neuroglioma cell line. The IC50 for viability was 12 mM. In (B), are
results of a dose-response treatment of H4-tau cells with harmine at the
indicated concentrations. Reductions to total tau and all three
phosphorylated forms of tau tested were observed. % control values
represent the amount of the respective tau forms present following
treatment with 8 mM harmine, although 0.8 mM harmine also reduced
phospho-tau levels significantly. Harmine treatment was performed as
described in the Methods. For (C), results for moclobemide, an MAO-A
selective antagonist, are shown. % control values represent the amount
of each form of tau present following treatment with the highest
500 mM concentration.
doi:10.1371/journal.pone.0019264.g002
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could be a critical regulator of tau function and dysfunction during
the course of AD. As such, targeting this kinase pharmacologically
may provide a means to modify the course of tau dysfunction and
pathology in AD and other tauopathies.
DYRK1A directly phosphorylates tau on serine 396
DYRK1A can directly phosphorylate tau protein on serine 396
(Figure 4A). Due to high baseline phosphorylation of tau on
threonine 231 and on the 12E8 epitope in these preparations of
recombinant tau (data not shown), we were unable to test for direct
tau phosphorylation by DYRK1A on these epitopes. However,
our data are consistent with these sites either being directly
phosphorylated by DYRK1A or being controlled by a pathway
that is dependent on DYRK1A activity. Whether these pathways
ultimately result in the direct phosphorylation of tau on T231 or
the 12E8 epitope or whether these sites are ultimately affected
through indirect mechanisms, such as altered tau protein half-life
resulting from decreased tau phosphorylation at other sites,
remains to be determined.
Harmine, a DYRK1A inhibitor, alters the expression of
multiple forms of phosphorylated tau
Based on our RNA interference data implicating DYRK1A in
the phosphorylation of tau protein at multiple sites (Figure 1), we
tested the high affinity DYRK1A inhibitor harmine for effects on
Figure 3. Multiple b-carboline derivatives affect levels of total tau and phosphorylated tau. Each indicated compound was tested at the
concentrations shown below each compound name. % control values represent the effect seen at the highest concentration tested for each
compound. 9-ethylharmine clearly showed the most potent effect in this assay, significantly reducing total and phospho tau levels at a 1 mM
concentration.
doi:10.1371/journal.pone.0019264.g003
b-Carboline Compounds Inhibit Tau Phosphorylation
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19264tau. Harmine showed a clear dose response profile for the
inhibition of tau phosphorylation (Figure 2B) at doses that elicited
no toxicity (Figure 2A). The increased toxicity that occurred at
higher concentrations prevented obtaining an IC50 for tau effects
in our cell-based tau assay. However, because harmine signifi-
cantly affected tau levels prior to observed toxicity, we conclude
that the toxicity seen at higher concentrations beyond 8 mM likely
results from excessive reductions to tau protein levels. This
Figure 4. Quantification of the inhibition of tau phosphorylation by multiple b-carbolines. Quantification of tau phosphorylation data
from the H4 cells is shown for each compound tested. The phospho-tau data have been normalized to account for any changes to total tau levels.
Effects on total tau are indicated in each graph. Significance at p,0.05, as assessed by Student’s T-test, is indicated by asterices above the error bars
on the graphs. Error bars (standard deviation) from three independent replicates are shown.
doi:10.1371/journal.pone.0019264.g004
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reductions to overall tau levels via siRNA knockdown of the tau
transcript, and concomitant decreases to levels of phosphorylated
tau, lead to significant cellular toxicity [7].
Although harmine significantly reduced total tau levels,
reductions to both 12E8 and pT231 phosphorylated tau remained
highly significant (Figure 4). However, interestingly, the reductions
to pS396 tau at higher concentrations mirror the reductions to
total tau levels. This is a somewhat striking observation since
DYRK1A can clearly directly phosphorylate tau protein on serine
396 (Figure 5) and suggests at least two possibilities. First,
phosphorylation of serine 396 could be very tightly correlated to
the overall stability of tau protein. Second, harmine and the other
b-carbolines, all of which show the same differential effect on the
relationship between pS396 tau and total tau (Figure 4), could
target additional cellular proteins that then lead to this S396/Total
Tau specific correlation. Further experiments will be needed to
account for the relationship between these compounds, pS396 tau,
total tau levels, and cellular toxicity.
b-carboline alkaloid derivatives alter the levels of
phosphorylated tau
Based on positive results for harmine, we tested several harmine
derivatives, including fully aromatic b-carboline compounds
(harmol, harmane, norharmane, 9-ethylharmine, and 3,4-substi-
tuted derivatives MPP-021 and MPP-313) and a dihydro-
derivative (harmaline). Modifications to certain structural compo-
nents of the b-carboline ring structure significantly affected the
ability of these compounds to inhibit tau phosphorylation. A
comparison of results for harmaline and harmine indicate that a
fully aromatic ring structure provides higher affinity for tau
inhibition and toxicity (see Table S1, Figure 2B, Figure 3,
Figure 6). Certain modifications to carbon 7 increase toxicity and
tau effects (compare harmine and harmol to harmane). Also, the
methyl group on carbon 1 appears to be important for the
observed tau effects and toxicity (compare norharmane to
harmane). Lastly, the addition of an ethyl group to N-9 increased
the effects of harmine on tau and increased toxicity (compare 9-
ethylharmine to harmine). The combination of results provide
insights into which structural features of harmine could be targeted
and altered to improve the tau effects.
Another important observation from these compound derivative
studies was that correlations between tau reductions and cellular
toxicity that were first observed with harmine, were also found with
all of the b-carbolines tested. While we were initially hopeful that
certain derivatives could separate the tau effects from the toxic effects,
no compounds separated these effects. This may well result from a
causative relationship between excessive tau reductions and toxicity,
consistent with our prior results targeting tau expression with siRNA
Figure 5. Harmine inhibits the DYRK1A catalyzed direct
phosphorylation of tau protein on serine 396. Shown in (A) are
results of an in vitro phosphorylation assay utilizing recombinant
DYRK1A and tau proteins. A doublet pS396 tau phosphorylation is
observed only in the presence of tau, DYRK1A, and ATP. In (B), harmine
potently inhibits the direct phosphorylation of tau protein by DYRK1A
with an IC50 of 0.7 mM.
doi:10.1371/journal.pone.0019264.g005
Figure 6. Structurally distinct b-carboline derivatives inhibit
DYRK1A-dependent pS396 tau phosphorylation with varying
affinities. Shown are in vitro phosphorylation results for all com-
pounds in this study. The compounds tested are indicated above the
respective western results for each compound. The concentrations (in
mM) are indicated at the top of the first panel and are the same for each
compound tested. The IC50 values calculated from these assays are
indicated in the right column, next to the western results for each
compound.
doi:10.1371/journal.pone.0019264.g006
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phosphorylation data at each drug concentration tested is shown. Error bars represent the standard deviation of three independent replicates.
Significance at p,0.01, as assessed by Student’s T-test, is indicated by a single asterix above the error bars on the graphs. Significance at p,0.001 is
indicated by two asterices above the error bars.
doi:10.1371/journal.pone.0019264.g007
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strategies designed against tau expression or phosphorylation.
Conclusions
Pharmacologic inhibition of tau phosphorylation at certain key
sites that regulate the functional activity of tau or that promote the
aggregation of tau in to neurofibrillary tangles may provide a
promising approach for the treatment of AD and other
tauopathies. We show that the b-carboline alkaloids inhibit
DYRK1A kinase activity and reduce the levels of multiple
phosphorylated forms of tau protein that are important in the
pathological progression of AD. Further refinement of this class of
compounds on functional groups that are important determinants
of their affinity for DYRK1A could lead to high affinity inhibitors
of tau phosphorylation.
Supporting Information
Figure S1 Quantification of the inhibition of tau phosphoryla-
tion by multiple b-carbolines. Quantification of the absolute tau
phosphorylation data from the H4 cells is shown for each
compound tested. Data have not been normalized to account for
changes to total tau levels. Significance at p,0.05, as assessed by
Student’s T-test, is indicated by asterices above the error bars on
the graphs. Error bars (standard deviation) from three independent
replicates are shown.
(TIF)
Table S1 b-carboline compounds tested in this study. Shown in
columns from left to right are the compound names, chemical
structures, concentration resulting in 50% viability in the H4
neuroglioma cell line used in all of the cell-based tau assays.
(TIF)
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